A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder.
about
Atypical Antipsychotics in Children with Pervasive Developmental DisordersSystematic review of the effectiveness of pharmacological treatments for adolescents and adults with autism spectrum disorderAsperger syndromeSelective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)Medications for adolescents and young adults with autism spectrum disorders: a systematic reviewCurrent developments in the genetics of autism: from phenome to genomeOff-label indications for atypical antipsychotics: A systematic reviewNetworking in autism: leveraging genetic, biomarker and model system findings in the search for new treatmentsAutism spectrum disorders: early detection, intervention, education, and psychopharmacological managementLack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autismNeurofeedback for autistic spectrum disorder: a review of the literaturePharmacotherapy to control behavioral symptoms in children with autismAutism and the serotonin transporter: the long and short of itAutism and serotonin transporter gene polymorphisms: a systematic review and meta-analysisOxidative pathways as a drug target for the treatment of autismHyperserotoninemia and altered immunity in autismTranslational Mouse Models of Autism: Advancing Toward Pharmacological Therapeutics.The disruption of Celf6, a gene identified by translational profiling of serotonergic neurons, results in autism-related behaviors.Reward processing in autism: a thematic series.Autism: current theories regarding its pathogenesis and implications for rational pharmacotherapy.Medication treatment in subjects with autistic spectrum disorders.Pharmacological management in children and adolescents with pervasive developmental disorder.Pharmacotherapy in children and adolescents with pervasive developmental disorders.Fluoxetine for Autistic Behaviors (FAB trial): study protocol for a randomized controlled trial in children and adolescents with autism.Physical mapping of the serotonin 5-HT(7) receptor gene (HTR7) to chromosome 10 and pseudogene (HTR7P) to chromosome 12, and testing of linkage disequilibrium between HTR7 and autistic disorder.Venlafaxine in children, adolescents, and young adults with autism spectrum disorders: an open retrospective clinical report.Occurrence of tics in Asperger's syndrome and autistic disorder.A double-blind, placebo-controlled crossover study investigating the effect of porcine secretin in children with autism.Emerging drugs for the treatment of symptoms associated with autism spectrum disorders.The effects of response interruption and redirection and sertraline on vocal stereotypy.A pharmacogenetic study of escitalopram in autism spectrum disordersInvestigation of two variants in the DOPA decarboxylase gene in patients with autism.The pathophysiology and treatment of autism.The psychiatric presentation of fragile x: evolution of the diagnosis and treatment of the psychiatric comorbidities of fragile X syndrome.Autism and the school nurse.New directions in the treatment of autism spectrum disorders from animal model research.The genetics of autism.Treating the core features of autism: are we there yet?Association study in siblings and case-controls of serotonin- and oxytocin-related genes with high functioning autism.
P2860
Q22241426-8240AF87-8A06-4515-BFEC-D316E7C68311Q22241792-ECAAEDF8-4135-4DA2-A8B4-62878D26B503Q22252681-E3849ED2-835D-4438-B276-3726B7FFD95DQ24200368-86A56C62-D279-4403-AA67-C1C6FB3C5AECQ24236316-5EB36B6F-0E3B-43B3-85DA-680001BFC628Q24563705-5C2093A5-247B-4D73-959B-501D23FC608DQ24646514-69E2B2A5-75DF-4310-983B-864308229504Q24803302-196D5663-BEB8-4271-B412-9242C91F5E9AQ26850307-D503ABD7-0886-47F4-ADC3-ECD1642B796EQ28212094-77C34032-317D-4A8E-9CA9-F390052DD179Q28247116-27042815-8CB5-4D98-900A-DAE2D1040A7EQ28262484-34B853E8-3FE3-4F80-A33B-9A18E0DDD12BQ28265801-66D1DEEB-148A-45E8-979C-47FEE5D80ADFQ28267610-2AA5E0FD-C251-4B1C-B5A2-82831FD7D4C8Q28269298-FF1EE2A1-D943-48FF-ACC2-09C4B638493DQ28295948-2CDB8097-F7B0-4C73-90FA-3C676B123673Q28307190-032BDAD6-7B8A-47D3-8390-3B965FB02223Q28394524-2456479C-D0FA-44F6-8F6B-CB9A5D43E4C0Q28508280-ABC59EEF-A812-4B19-9270-23C1CAEE1CBEQ30462673-C0110CB3-4ED6-4797-AAE6-832368573FB2Q30607088-5730A3EC-B621-433C-8C02-2CBD31F2A649Q30623213-B4A78ACF-57B9-4D70-9732-BDEAC06A4411Q33521748-510E3E14-80AE-4FAE-B01E-CBB318E06E5CQ33646475-42303254-78B8-46E2-BE1B-4B9FFE47FAD4Q33794328-94022D98-1339-4C38-8EC3-81814152B053Q33874461-81907A69-1F2E-4FEC-96DD-F6EBEE3E7A86Q33891726-A69844AC-8147-4503-9703-FC8DF482046BQ33906986-0E204615-7C72-4C3B-9848-1FF4732AA222Q33957170-218C5C06-C800-461C-8361-7F677FC3D763Q34073325-FA0F20F5-D7BD-4DBE-B335-518E3A1AD3E4Q34118336-722FB69D-D08E-4966-A4BF-E321E9ED6E8BQ34118665-37478D26-0271-4DDB-AD4E-4F30785FD42AQ34126958-0F2739AC-C68C-4F27-B173-56E9DDA84730Q34200042-B7E84C82-C549-4D32-A4A8-A7EF62C76C27Q34213731-D3EE232A-FFBC-4560-A093-4951E232F754Q34226208-C7C85875-5DC0-40AE-A94D-B78BEE0C614AQ34267391-83FCA361-C24F-42C2-AE97-6AB31E8AA318Q34278925-63216F0A-8BE9-4449-B18B-12FAB456BF16Q34387327-914E5142-8092-4241-89A6-78DFD30A4477Q34470381-66295CF0-23AD-401F-A4D3-C4B3ABAC6C68
P2860
A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh-hant
name
A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder.
@en
A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder.
@nl
type
label
A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder.
@en
A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder.
@nl
prefLabel
A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder.
@en
A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder.
@nl
P2093
P1433
P1476
A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder.
@en
P2093
P304
P356
10.1001/ARCHPSYC.1996.01830110037005
P407
P577
1996-11-01T00:00:00Z